Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis.

Dutta D, Kumar M, Shivaprasad KS, Kumar A, Sharma M

Diabetes & metabolic syndrome10 Jun 2022Cited by 21 (Europe PMC)

PMID35709586DOI10.1016/j.dsx.2022.102539PepBankPUB-35709586

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanSystematic reviewEfficacy outcome
In people with MAFLD or type 2 diabetes, injectable semaglutide lowered ALT more than the comparison in a meta-analysis.
In plain wordsIn people with fatty liver disease or type 2 diabetes, semaglutide injections lowered the liver enzyme ALT.
Peptide
Semaglutide
Outcome
DecreaseAlanine aminotransferase (ALT) change
Study
n = 2,050
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Studied dose
0.4 mg/0.5 mg once weekly · injectableAs given in this study (human).
Measurements
Mean difference ALT
−3.89 U/L
semaglutide
Source sentences
Summary
ALT [MD -3.89U/L (95%CI: -5.41 to -2.36); P 2 = 0%; 2050 patients]
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving people with MAFLD and/or type-2 diabetes (T2DM) receiving semaglutide.
Summary · context
Data from 4 RCTs (2115 patients) was analysed.
Report a problemFND-3570958601
02HumanSystematic reviewEfficacy outcome
In people with MAFLD or type 2 diabetes, injectable semaglutide lowered HbA1c in a meta-analysis.
In plain wordsIn people with fatty liver disease or type 2 diabetes, semaglutide injections lowered HbA1c, a measure of blood sugar control.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change
Study
n = 2,115
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.4 mg/0.5 mg once weekly · injectableAs given in this study (human).
Measurements
Mean difference HbA1c
−0.77%
semaglutide
Source sentences
Summary
HbA1c [MD -0.77% (95%CI: 1.10 to -0.45); P = 0.002; I² = 100%; 2115 patients]
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving people with MAFLD and/or type-2 diabetes (T2DM) receiving semaglutide.
Summary · context
Data from 4 RCTs (2115 patients) was analysed.
Report a problemFND-3570958608
03HumanSystematic reviewEfficacy outcome
In people with MAFLD or type 2 diabetes, injectable semaglutide lowered triglycerides in a meta-analysis.
In plain wordsIn people with fatty liver disease or type 2 diabetes, semaglutide injections lowered triglycerides.
Peptide
Semaglutide
Outcome
DecreaseTriglycerides
Study
n = 2,050
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Studied dose
0.4 mg/0.5 mg once weekly · injectableAs given in this study (human).
Measurements
Mean difference triglycerides
−21.43 mg/dl
semaglutide
Source sentences
Summary
triglycerides [MD -21.43 mg/dl (95% CI: 41.63 to -1.23); P = 0.04; I² = 99%; 2050 patients]
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving people with MAFLD and/or type-2 diabetes (T2DM) receiving semaglutide.
Summary · context
Data from 4 RCTs (2115 patients) was analysed.
Report a problemFND-3570958604
04HumanSystematic reviewEfficacy outcome
In people with MAFLD or type 2 diabetes, injectable semaglutide lowered total cholesterol in a meta-analysis.
In plain wordsIn people with fatty liver disease or type 2 diabetes, semaglutide injections lowered total cholesterol.
Peptide
Semaglutide
Outcome
DecreaseTotal cholesterol
Study
n = 1,888
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Studied dose
0.4 mg/0.5 mg once weekly · injectableAs given in this study (human).
Measurements
Mean difference total cholesterol
−5.53 mg/dl
semaglutide
Source sentences
Summary
total cholesterol [MD -5.53 mg/dl (95% CI: -8.45 to -2.61); P 2 = 0%; 1888 patients]
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving people with MAFLD and/or type-2 diabetes (T2DM) receiving semaglutide.
Summary · context
Data from 4 RCTs (2115 patients) was analysed.
Report a problemFND-3570958605
05HumanSystematic reviewEfficacy outcome
In people with MAFLD or type 2 diabetes, injectable semaglutide lowered LDL-cholesterol in a meta-analysis.
In plain wordsIn people with fatty liver disease or type 2 diabetes, semaglutide injections lowered LDL cholesterol.
Peptide
Semaglutide
Outcome
DecreaseLDL-cholesterol
Study
n = 1,888
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Studied dose
0.4 mg/0.5 mg once weekly · injectableAs given in this study (human).
Measurements
Mean difference LDL-cholesterol
−3.55 mg/dl
semaglutide
Source sentences
Summary
LDL-cholesterol [MD -3.55 mg/dl (95% CI: -5.87 to -1.23); P 2 = 0%; 1888 patients]
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving people with MAFLD and/or type-2 diabetes (T2DM) receiving semaglutide.
Summary · context
Data from 4 RCTs (2115 patients) was analysed.
Report a problemFND-3570958606
06HumanSystematic reviewEfficacy outcome
In people with MAFLD or type 2 diabetes, injectable semaglutide lowered liver stiffness measured by fibroscan in a meta-analysis.
In plain wordsIn people with fatty liver disease or type 2 diabetes, semaglutide injections lowered liver stiffness.
Peptide
Semaglutide
Outcome
DecreaseLiver stiffness (fibroscan)
Study
n = 162
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
0.4 mg/0.5 mg once weekly · injectableAs given in this study (human).
Measurements
Mean difference liver stiffness
−3.19 kPa
semaglutide
Source sentences
Summary
liver stiffness (fibroscan®) [MD -3.19 kPa (95%CI: -3.26 to -3.12); P < 0.01; 162 patients]
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving people with MAFLD and/or type-2 diabetes (T2DM) receiving semaglutide.
Summary · context
Data from 4 RCTs (2115 patients) was analysed.
Report a problemFND-3570958602
07HumanSystematic reviewEfficacy outcome
In people with MAFLD or type 2 diabetes, injectable semaglutide lowered steatosis in a meta-analysis.
In plain wordsIn people with fatty liver disease or type 2 diabetes, semaglutide injections lowered liver fat.
Peptide
Semaglutide
Outcome
DecreaseHepatic steatosis
Study
n = 162
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
0.4 mg/0.5 mg once weekly · injectableAs given in this study (human).
Measurements
Mean difference steatosis
−13.4 dB/m
semaglutide
Source sentences
Summary
steatosis [MD -13.40 dB/m (95%CI: 20.56 to -6.24); P < 0.01; 162 patients]
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving people with MAFLD and/or type-2 diabetes (T2DM) receiving semaglutide.
Summary · context
Data from 4 RCTs (2115 patients) was analysed.
Report a problemFND-3570958603
08HumanSystematic reviewSafety outcome
In people with MAFLD or type 2 diabetes, treatment-emergent adverse events were comparable between semaglutide and the comparison.
In plain wordsIn people with fatty liver disease or type 2 diabetes, side effects overall were similar with semaglutide and the comparison.
Peptide
Semaglutide
Outcome
No significant changeTreatment-emergent adverse events
Study
n: not reported in source
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
0.4 mg/0.5 mg once weekly · injectableAs given in this study (human).
Measurements
RR
2.31 ratio
treatment-emergent adverse events
Source sentences
Summary
Occurrence of treatment-emergent adverse-events [RR 2.31 (95% CI: 0.76-7.06); P = 0.14; I² = 82%]
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving people with MAFLD and/or type-2 diabetes (T2DM) receiving semaglutide.
Summary · context
Data from 4 RCTs (2115 patients) was analysed.
Report a problemFND-3570958609
09HumanSystematic reviewSafety outcome
In people with MAFLD or type 2 diabetes, severe adverse events were comparable between semaglutide and the comparison.
In plain wordsIn people with fatty liver disease or type 2 diabetes, severe side effects were similar with semaglutide and the comparison.
Peptide
Semaglutide
Outcome
No significant changeSevere adverse events
Study
n: not reported in source
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
0.4 mg/0.5 mg once weekly · injectableAs given in this study (human).
Measurements
RR
1.07 ratio
severe adverse events
Source sentences
Summary
severe adverse events [RR 1.07 (95%CI: 0.69-1.65); P = 0.77; I² = 33%] were comparable.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving people with MAFLD and/or type-2 diabetes (T2DM) receiving semaglutide.
Summary · context
Data from 4 RCTs (2115 patients) was analysed.
Report a problemFND-3570958610
10HumanSystematic reviewSafety outcome
In people with MAFLD or type 2 diabetes, adverse events leading to trial discontinuation were higher with semaglutide than with the comparison.
In plain wordsIn people with fatty liver disease or type 2 diabetes, more people stopped the trial because of side effects with semaglutide.
Peptide
Semaglutide
Outcome
IncreaseAdverse events leading to trial discontinuation
Study
n: not reported in source
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
0.4 mg/0.5 mg once weekly · injectableAs given in this study (human).
Measurements
RR
2.37 ratio
discontinuation
Source sentences
Summary
Adverse-events leading to trial discontinuation [RR 2.37 (95% CI: 1.33-4.22); P = 0.003; I² = 24%]
3 context sentences(design, population, supporting numbers)
Summary · context
were higher with semaglutide.
Summary · context
Electronic databases were searched for RCTs involving people with MAFLD and/or type-2 diabetes (T2DM) receiving semaglutide.
Summary · context
Data from 4 RCTs (2115 patients) was analysed.
Report a problemFND-3570958611
11HumanSystematic reviewSafety outcome
In people with MAFLD or type 2 diabetes, diarrhea was more frequent with semaglutide than with the comparison.
In plain wordsIn people with fatty liver disease or type 2 diabetes, diarrhea happened more often with semaglutide.
Peptide
Semaglutide
Outcome
IncreaseDiarrhea
Study
n: not reported in source
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.4 mg/0.5 mg once weekly · injectableAs given in this study (human).
Measurements
RR
2.05 ratio
diarrhea
Source sentences
Summary
diarrhea [RR 2.05 (95%CI: 1.17-3.60); P = 0.01; I² = 66%]
3 context sentences(design, population, supporting numbers)
Summary · context
were higher with semaglutide.
Summary · context
Electronic databases were searched for RCTs involving people with MAFLD and/or type-2 diabetes (T2DM) receiving semaglutide.
Summary · context
Data from 4 RCTs (2115 patients) was analysed.
Report a problemFND-3570958612
12HumanSystematic reviewSafety outcome
In people with MAFLD or type 2 diabetes, nausea was more frequent with semaglutide than with the comparison.
In plain wordsIn people with fatty liver disease or type 2 diabetes, nausea happened more often with semaglutide.
Peptide
Semaglutide
Outcome
IncreaseNausea
Study
n: not reported in source
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.4 mg/0.5 mg once weekly · injectableAs given in this study (human).
Measurements
RR
4.98 ratio
nausea
Source sentences
Summary
nausea [RR 4.98 (95%CI: 3.23-7.67); P 2 = 0%]
3 context sentences(design, population, supporting numbers)
Summary · context
were higher with semaglutide.
Summary · context
Electronic databases were searched for RCTs involving people with MAFLD and/or type-2 diabetes (T2DM) receiving semaglutide.
Summary · context
Data from 4 RCTs (2115 patients) was analysed.
Report a problemFND-3570958613
13HumanSystematic reviewSafety outcome
In people with MAFLD or type 2 diabetes, vomiting was more frequent with semaglutide than with the comparison.
In plain wordsIn people with fatty liver disease or type 2 diabetes, vomiting happened more often with semaglutide.
Peptide
Semaglutide
Outcome
IncreaseVomiting
Study
n: not reported in source
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.4 mg/0.5 mg once weekly · injectableAs given in this study (human).
Measurements
RR
3.9 ratio
vomiting
Source sentences
Summary
vomiting [RR 3.90 (95%CI: 1.75-8.68); P 2 = 54%]
3 context sentences(design, population, supporting numbers)
Summary · context
were higher with semaglutide.
Summary · context
Electronic databases were searched for RCTs involving people with MAFLD and/or type-2 diabetes (T2DM) receiving semaglutide.
Summary · context
Data from 4 RCTs (2115 patients) was analysed.
Report a problemFND-3570958614
14HumanSystematic reviewEfficacy outcome
In people with MAFLD or type 2 diabetes, injectable semaglutide reduced percent body weight in a meta-analysis.
In plain wordsIn people with fatty liver disease or type 2 diabetes, semaglutide injections lowered body weight.
Peptide
Semaglutide
Outcome
DecreasePercent body weight change
Study
n = 2,115
Outcome group
Body weight · Metabolic and weight
Studied dose
0.4 mg/0.5 mg once weekly · injectableAs given in this study (human).
Measurements
Mean difference percent weight
−8.99%
semaglutide
Source sentences
Summary
percent-weight [MD -8.99% (95%CI: -14.64 to -3.34); P = 0.002; I² = 100%; 2115 patient]
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving people with MAFLD and/or type-2 diabetes (T2DM) receiving semaglutide.
Summary · context
Data from 4 RCTs (2115 patients) was analysed.
Report a problemFND-3570958607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.